Abbott Labs continues Dx winning streak with bladder cancer biomarker deal

Abbott Laboratories' ($ABT) diagnostics unit posted sizable gains in 2014, and the company is continuing to chart positive momentum in the new year with a licensing deal with the Institut Curie. Under the agreement, Abbott will gain exclusive rights for FGFR3 gene mutations for use in bladder cancer, helping the company expand its footprint in molecular diagnostics. Release

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.